Home / Business and Economy / Zydus Facility Inspection Concludes With One USFDA Observation
Zydus Facility Inspection Concludes With One USFDA Observation
29 Sep
Summary
- USFDA inspection at Zydus SEZ II plant concluded with one observation.
- No data integrity issues were identified during the USFDA inspection.
- Zydus Lifesciences to promptly address the single observation with USFDA.
The US Food and Drug Administration (USFDA) has concluded its inspection of Zydus Lifesciences' SEZ II manufacturing facility in Ahmedabad. The inspection, which took place from September 21 to September 28, 2026, resulted in one observation.
Significantly, the USFDA's review did not identify any issues related to data integrity. Zydus Lifesciences has committed to working closely with the USFDA to address the single observation promptly.
This development follows a routine inspection process, and the company's proactive approach to resolving the noted observation underscores its commitment to maintaining high manufacturing standards.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
